Plant Name: Rheum tanguticum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| CNR1; DRD3; DRD2; HCAR2; CNR2; | |
| ALPL; RECQL; TDP1; BLM; PKM; HKDC1; PIK3CA; PIK3CB; HPGD; HSD11B2; AKR1B1; HSD17B10; ALOX15; HSD11B1; AKR1B10; PGD; NQO2; ALDH1A1; ALOX12; GFER; USP2; UBE2N; UGT1A1; APEX1; POLB; | |
| HDAC6; HDAC10; HDAC3; HDAC8; HDAC1; HDAC2; | |
| PTPN1; CDC25B; | |
| ACHE; GAA; | |
| BCL2; | |
| KCNH2; | |
| AKT1; MET; MAP2K1; CSNK2A1; SYK; NEK2; NEK6; GRK6; SRC; IGF1R; PTK2; AURKB; CDK1; MAPK1; MAPK14; PIM1; NUAK1; ALK; AXL; KDR; PLK1; PKN1; | |
| CA12; CA5B; CA3; CA14; CA5A; CA1; CA9; CA13; CA7; CA4; CA6; CA2; | |
| RXRA; | |
| ESR1; ESR2; | |
| KDM4E; | |
| MAOA; ALOX5; PTGS1; PTGS2; XDH; | |
| KDM4A; L3MBTL1; SMN1;SMN2; | |
| ELANE; | |
| MMP2; MMP9; MMP1; | |
| BACE1; | |
| HIF1A; NFKB1; TP53; | |
| FUT7; | |
| SLC6A2; SLCO1B3; SLCO1B1; | |
| LMNA; MCL1; MAPT; GMNN; HTT; NPC1; APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD11B2 | 11-beta-hydroxysteroid dehydrogenase 2 | P80365 | CHEMBL3746 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | UBE2N | Ubiquitin-conjugating enzyme E2 N | P61088 | CHEMBL6089 |
| Enzyme_unclassified | UGT1A1 | UDP-glucuronosyltransferase 1-1 | P22309 | CHEMBL1287617 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HKDC1 | Putative hexokinase HKDC1 | Q2TB90 | CHEMBL1741200 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Histone deacetylase | HDAC6 | Histone deacetylase 6 | Q9UBN7 | CHEMBL1865 |
| Histone deacetylase | HDAC10 | Histone deacetylase 10 | Q969S8 | CHEMBL5103 |
| Histone deacetylase | HDAC3 | Histone deacetylase 3 | O15379 | CHEMBL1829 |
| Histone deacetylase | HDAC8 | Histone deacetylase 8 | Q9BY41 | CHEMBL3192 |
| Histone deacetylase | HDAC1 | Histone deacetylase 1 | Q13547 | CHEMBL325 |
| Histone deacetylase | HDAC2 | Histone deacetylase 2 | Q92769 | CHEMBL1937 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Methyl-lysine/arginine binding protein | KDM4A | Lysine-specific demethylase 4A | O75164 | CHEMBL5896 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Nuclear hormone receptor subfamily 2 group B | RXRA | Retinoid X receptor alpha | P19793 | CHEMBL2061 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Potassium channels | KCNH2 | HERG | Q12809 | CHEMBL240 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | PLK1 | Serine/threonine-protein kinase PLK1 | P53350 | CHEMBL3024 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | Q02750 | CHEMBL3587 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | GRK6 | G protein-coupled receptor kinase 6 | P43250 | CHEMBL6144 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Serine protease | ELANE | Leukocyte elastase | P08246 | CHEMBL248 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | CNR1 | Cannabinoid CB1 receptor | P21554 | CHEMBL218 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Small molecule receptor (family A GPCR) | CNR2 | Cannabinoid CB2 receptor | P34972 | CHEMBL253 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | GMNN | Geminin | O75496 | CHEMBL1293278 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 4.471E-13 | 1.909E-10 | AURKB, CA2, CA7, CNR1, DRD2, DRD3, HCAR2, HIF1A, HTT, MAPK1, MAPK14, NEK2, NPC1, PIK3CB, PTGS2, SYK |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 7.000E-12 | 2.060E-09 | AURKB, BCL2, CA2, CA7, CNR1, DRD2, DRD3, HCAR2, HDAC8, HIF1A, HTT, KDR, MAPK1, MAPK14, NEK2, NPC1, PIK3CB, PTGS2, SRC, SYK |
| MF | GO:0003824; catalytic activity | GO:0032041; NAD-dependent histone deacetylase activity (H3-K14 specific) | 1.856E-11 | 4.671E-09 | HDAC1, HDAC10, HDAC2, HDAC3, HDAC6, HDAC8 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 7.620E-11 | 1.747E-08 | BLM, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, HDAC6, KDM4A, L3MBTL1, MMP1, MMP2, MMP9, NQO2, PTPN1, RXRA, TP53 |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 1.152E-10 | 2.483E-08 | ALPL, AXL, CNR1, CNR2, CYP1A1, CYP1A2, ELANE, HDAC1, HDAC2, HPGD, MAPK14, NFKB1, PTGS2, SRC, UGT1A1 |
| BP | GO:0008152; metabolic process | GO:0070932; histone H3 deacetylation | 1.490E-09 | 2.317E-07 | HDAC1, HDAC10, HDAC2, HDAC3, HDAC6, HDAC8 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.762E-09 | 2.683E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.768E-09 | 2.683E-07 | AKT1, ALK, AURKB, CDK1, CSNK2A1, GRK6, MAP2K1, MAPK1, MAPK14, NEK2, NEK6, NUAK1, PIK3CA, PIM1, PKN1, PLK1, SYK |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.985E-09 | 2.960E-07 | AKT1, ALK, AURKB, AXL, BLM, CDK1, CSNK2A1, GRK6, HKDC1, IGF1R, KDR, MAP2K1, MAPK1, MAPK14, MET, NEK2, NEK6, NUAK1, PIK3CA, PIK3CB, PIM1, PKM, PKN1, PLK1, PTK2, RECQL, SRC, SYK, TP53, UBE2N |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.316E-09 | 4.658E-07 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.157E-09 | 6.889E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, PTGS1, PTGS2, SRC |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 8.817E-09 | 1.079E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0042826; histone deacetylase binding | 1.766E-08 | 1.913E-06 | GMNN, HDAC1, HDAC10, HDAC2, HDAC3, HDAC6, HIF1A, PKN1, TP53 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.835E-08 | 1.968E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 2.967E-08 | 3.033E-06 | BCL2, MCL1, PIK3CA, PTK2, SRC |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.967E-08 | 3.033E-06 | ALOX12, ALOX15, ALOX5, HPGD, PTGS2 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 3.285E-08 | 3.311E-06 | CSNK2A1, HDAC6, HDAC8, HIF1A, KDR, MAPT |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 6.603E-08 | 6.197E-06 | AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APP, AURKB, BCL2, BLM, CA1, CA13, CA2, CA3, CA7, CDC25B, CDK1, CSNK2A1, GFER, GMNN, HDAC1, HDAC3, HDAC6, HDAC8, HIF1A, HKDC1, HPGD, HTT, KDM4A, LMNA, MAP2K1, MAPK1, MAPK14, MAPT, MCL1, NEK2, NEK6, NFKB1, NQO2, PGD, PIK3CA, PIK3CB, PIM1, PKM, PKN1, PLK1, PTK2, PTPN1, SMN1, SMN2, SRC, SYK, TP53, UBE2N, XDH |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 7.832E-08 | 7.226E-06 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, HDAC2, HDAC6 |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 1.043E-07 | 9.258E-06 | AKT1, BCL2, HIF1A, MCL1, MMP9, PTGS2, PTPN1, SRC |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 1.083E-07 | 9.546E-06 | AKT1, AURKB, BLM, CSNK2A1, HDAC1, HDAC2, L3MBTL1, MAPK14, NUAK1, TP53 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.350E-07 | 1.171E-05 | CYP1A1, HDAC1, HDAC2, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.350E-07 | 1.171E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0035094; response to nicotine | 1.560E-07 | 1.327E-05 | BCL2, CNR1, DRD2, HDAC2, MAPK1, NFKB1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.210E-07 | 1.830E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 2.505E-07 | 2.035E-05 | AXL, KDR, MAPK14, PIK3CA, PIK3CB, PTK2, SRC |
| BP | GO:0008152; metabolic process | GO:0010870; positive regulation of receptor biosynthetic process | 3.944E-07 | 3.024E-05 | HDAC1, HDAC2, HDAC6, HIF1A |
| BP | GO:0050896; response to stimulus | GO:0001975; response to amphetamine | 4.259E-07 | 3.220E-05 | CNR2, DRD2, DRD3, HDAC1, HDAC2 |
| BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 4.911E-07 | 3.638E-05 | CA3, CDK1, CNR1, DRD3, HPGD, POLB, TP53, UGT1A1 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.889E-07 | 4.246E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 6.303E-07 | 4.471E-05 | AKT1, BCL2, MAPT, PTPN1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.405E-07 | 5.737E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0023052; signaling | GO:0032228; regulation of synaptic transmission, GABAergic | 1.267E-06 | 8.235E-05 | CA2, CA7, CNR1, CNR2, DRD2 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.084E-06 | 1.813E-04 | AKT1, BCL2, HIF1A, LMNA, PTGS2, SRC, TP53 |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 3.948E-06 | 2.286E-04 | BLM, HDAC1, HIF1A, HTT, NUAK1, TP53 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 4.485E-06 | 2.577E-04 | AKT1, AXL, MAPK1, PIK3CA, PIK3CB, SRC, SYK |
| BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 6.451E-06 | 3.521E-04 | AKT1, HIF1A, KDR, MAPK14, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0071498; cellular response to fluid shear stress | 6.829E-06 | 3.690E-04 | CA2, HDAC3, PTGS2, SRC |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 7.699E-06 | 4.050E-04 | AKT1, APEX1, BCL2, CA5A, CA5B, CDK1, CYP1A1, CYP1B1, ESR2, GFER, HKDC1, HSD17B10, MAOA, MAP2K1, MAPK1, MAPK14, MCL1, MMP2, NFKB1, PKM, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 8.982E-06 | 4.673E-04 | IGF1R, KDR, PTK2, SRC, SYK |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 9.671E-06 | 4.978E-04 | AKT1, CDC25B, ESR1, HIF1A, MAPK1, MAPK14, NEK6, PKN1, PLK1, PTK2, PTPN1, SRC, SYK, TP53 |
| MF | GO:0005488; binding | GO:0003682; chromatin binding | 9.939E-06 | 5.083E-04 | APEX1, CDK1, ESR1, GMNN, HDAC1, HDAC2, HDAC3, HDAC8, L3MBTL1, NFKB1, PKN1, RXRA, TP53 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.309E-05 | 6.480E-04 | CYP3A4, ESR1, ESR2, HSD11B2, NPC1, UGT1A1 |
| CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 1.633E-05 | 7.901E-04 | AURKB, CDK1, HDAC3, PLK1, POLB |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 1.701E-05 | 8.157E-04 | AKT1, MAPK14, MAPT, PTGS2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 1.727E-05 | 8.263E-04 | BLM, RECQL, TP53 |
| BP | GO:0009987; cellular process | GO:0000226; microtubule cytoskeleton organization | 1.734E-05 | 8.281E-04 | AURKB, CDK1, HDAC3, HTT, LMNA, MAPT, NEK2, NEK6, PLK1, PTK2 |
| BP | GO:0032501; multicellular organismal process | GO:0032922; circadian regulation of gene expression | 1.961E-05 | 9.201E-04 | DRD2, DRD3, HDAC1, HDAC2, USP2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.493E-25 | 5.980E-21 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0051059; NF-kappaB binding | 2.262E-05 | 1.048E-03 | APEX1, HDAC1, HDAC2, HDAC3 |
| BP | GO:0009987; cellular process | GO:0051983; regulation of chromosome segregation | 2.317E-05 | 1.071E-03 | AURKB, CSNK2A1, HDAC8, NEK2, NEK6, PLK1 |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 2.355E-05 | 1.086E-03 | AKR1B1, APP, BACE1, CA2, CNR1, CNR2, DRD2, DRD3, HDAC1, HDAC6, HIF1A, HTT, MAPK1, MAPT, PIK3CA, PKM, PTGS2, PTK2, SLC6A2, SMN1, SMN2, SRC |
| CC | GO:0044464; cell part | GO:0030424; axon | 2.509E-05 | 1.138E-03 | APP, BACE1, CA2, CNR1, DRD2, HDAC6, HTT, MAPK1, MAPT |
| BP | GO:0009987; cellular process | GO:0010639; negative regulation of organelle organization | 2.602E-05 | 1.178E-03 | AKT1, HDAC6, HDAC8, KDM4A, LMNA, MAPT, MET, NEK2, PLK1, SRC |
| MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 3.362E-05 | 1.479E-03 | IGF1R, PIK3CA, PIK3CB |
| BP | GO:0050896; response to stimulus | GO:0042220; response to cocaine | 3.428E-05 | 1.493E-03 | CNR1, DRD2, DRD3, HDAC2 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 3.428E-05 | 1.493E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 3.428E-05 | 1.493E-03 | ALOX12, ALOX15, ALOX5, SYK |
| BP | GO:0050896; response to stimulus | GO:0010039; response to iron ion | 3.428E-05 | 1.493E-03 | BCL2, CYP1A1, DRD2, HIF1A |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 3.576E-05 | 1.527E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 3.576E-05 | 1.527E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0004714; transmembrane receptor protein tyrosine kinase activity | 3.527E-05 | 1.527E-03 | ALK, AXL, IGF1R, KDR, MET |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 3.576E-05 | 1.527E-03 | PTGS1, PTGS2 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 3.576E-05 | 1.527E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 3.576E-05 | 1.527E-03 | ALOX12, ALOX15 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 3.711E-05 | 1.569E-03 | BCL2, CA2, CA7, DRD2, DRD3, HTT, KDR, SRC |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 4.463E-05 | 1.851E-03 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0032501; multicellular organismal process | GO:0040014; regulation of multicellular organism growth | 5.140E-05 | 2.112E-03 | APP, BCL2, DRD2, DRD3, PIK3CA |
| BP | GO:0009987; cellular process | GO:0071396; cellular response to lipid | 5.760E-05 | 2.331E-03 | AKT1, AXL, ESR1, HDAC2, HDAC8, MAPK14, NFKB1, NPC1, SRC, UGT1A1 |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 6.462E-05 | 2.596E-03 | ALOX15, ESR1, HDAC6, MAPT, MET, MMP1, SRC, TP53 |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 6.805E-05 | 2.724E-03 | CNR2, DRD2, HDAC6, MAPK1, SMN1, SMN2 |
| CC | GO:0044464; cell part | GO:0031234; extrinsic component of cytoplasmic side of plasma membrane | 7.271E-05 | 2.884E-03 | ALOX15, CNR2, PTK2, SRC, SYK |
| BP | GO:0008152; metabolic process | GO:0000122; negative regulation of transcription from RNA polymerase II promoter | 7.296E-05 | 2.885E-03 | AURKB, DRD3, ELANE, ESR1, ESR2, HDAC1, HDAC10, HDAC2, HDAC3, HDAC8, NFKB1, PLK1, RXRA, TP53, USP2 |
| BP | GO:0032502; developmental process | GO:0060065; uterus development | 7.320E-05 | 2.887E-03 | CYP19A1, ESR1, SRC |
| BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 7.785E-05 | 3.043E-03 | MMP2, MMP9, PTGS2, RXRA |
| MF | GO:0003824; catalytic activity | GO:0032451; demethylase activity | 8.635E-05 | 3.363E-03 | CYP1A1, CYP1A2, KDM4A, KDM4E |
| BP | GO:0023052; signaling | GO:0050806; positive regulation of synaptic transmission | 9.029E-05 | 3.504E-03 | APP, CA2, CA7, DRD2, MAPK1, PTGS2 |
| MF | Unclassified; | GO:0004708; MAP kinase kinase activity | 9.110E-05 | 3.530E-03 | MAP2K1, MAPK1, MAPK14 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 9.419E-05 | 3.637E-03 | AXL, CDK1, CSNK2A1, PKM, UGT1A1 |
| BP | GO:0007610; behavior | GO:0007626; locomotory behavior | 1.041E-04 | 3.983E-03 | ALK, APP, DRD2, DRD3, GAA, NPC1, USP2 |
| BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 1.068E-04 | 4.004E-03 | DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.068E-04 | 4.004E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0033602; negative regulation of dopamine secretion | 1.068E-04 | 4.004E-03 | CNR1, DRD2 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.068E-04 | 4.004E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.068E-04 | 4.004E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004949; cannabinoid receptor activity | 1.068E-04 | 4.004E-03 | CNR1, CNR2 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.068E-04 | 4.004E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.068E-04 | 4.004E-03 | ALOX12, ALOX15 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.321E-04 | 4.828E-03 | CA2, CA4, CA9, HPGD, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0009987; cellular process | GO:0038096; Fc-gamma receptor signaling pathway involved in phagocytosis | 1.341E-04 | 4.875E-03 | MAPK1, PIK3CA, PIK3CB, PTK2, SRC, SYK |
| BP | GO:0051179; localization | GO:2000641; regulation of early endosome to late endosome transport | 1.350E-04 | 4.881E-03 | MAP2K1, MAPK1, SRC |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.350E-04 | 4.881E-03 | AURKB, MAPK1, NEK2 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.350E-04 | 4.881E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0045862; positive regulation of proteolysis | 1.357E-04 | 4.894E-03 | AKT1, APP, CDK1, HDAC2, MAPK14, MAPT, PLK1, PTK2, SRC, XDH |
| BP | GO:0009987; cellular process | GO:0007077; mitotic nuclear envelope disassembly | 1.393E-04 | 4.995E-03 | CDK1, LMNA, NEK6, PLK1 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.393E-04 | 4.995E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 1.421E-04 | 5.082E-03 | AKR1B1, AKT1, HDAC2, KDR, MMP2, PTGS2, RXRA, SRC, TP53 |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 1.521E-04 | 5.369E-03 | AKT1, LMNA, MMP9, TP53 |
| BP | GO:0009987; cellular process | GO:0034605; cellular response to heat | 1.521E-04 | 5.369E-03 | HDAC2, MAPT, PTGS2, TP53 |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 1.602E-04 | 5.627E-03 | ACHE, ALDH1A1, IGF1R, NQO2, PKM |
| BP | GO:0009987; cellular process | GO:1903599; positive regulation of autophagy of mitochondrion | 1.612E-04 | 5.636E-03 | HDAC6, HIF1A, HTT |
| BP | GO:0050896; response to stimulus | GO:0031000; response to caffeine | 1.612E-04 | 5.636E-03 | HDAC1, HDAC2, TP53 |
| CC | GO:0044464; cell part | GO:0005770; late endosome | 1.649E-04 | 5.707E-03 | BACE1, HDAC6, HTT, MAP2K1, MAPK1, SRC |
| BP | GO:0032501; multicellular organismal process | GO:0050769; positive regulation of neurogenesis | 1.909E-04 | 6.426E-03 | APP, BCL2, CNR1, DRD2, HDAC1, HDAC2, HIF1A, KDM4A, MAP2K1, MAPT |
| BP | GO:0008152; metabolic process | GO:0006091; generation of precursor metabolites and energy | 1.953E-04 | 6.504E-03 | AKR1B1, AKT1, CYP19A1, CYP1A2, GAA, HKDC1, NQO2, PKM, XDH |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 1.959E-04 | 6.504E-03 | APP, DRD2, DRD3, HIF1A |
| BP | GO:0007610; behavior | GO:0030534; adult behavior | 2.010E-04 | 6.651E-03 | ALK, APP, DRD2, DRD3, HDAC2, NPC1 |
| BP | GO:0008152; metabolic process | GO:0001523; retinoid metabolic process | 2.096E-04 | 6.895E-03 | AKR1B10, ALDH1A1, CYP1A1, CYP1B1, UGT1A1 |
| BP | GO:0009987; cellular process | GO:0038171; cannabinoid signaling pathway | 2.128E-04 | 6.938E-03 | CNR1, CNR2 |
| BP | GO:0009987; cellular process | GO:0090170; regulation of Golgi inheritance | 2.128E-04 | 6.938E-03 | MAP2K1, MAPK1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.128E-04 | 6.938E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 2.128E-04 | 6.938E-03 | ESR1, ESR2 |
| BP | GO:0065007; biological regulation | GO:0043393; regulation of protein binding | 2.403E-04 | 7.731E-03 | APP, AURKB, BCL2, MET, MMP9, PLK1, SRC |
| BP | GO:0009987; cellular process | GO:0007093; mitotic cell cycle checkpoint | 2.444E-04 | 7.848E-03 | AURKB, BLM, CDK1, PLK1, TP53 |
| BP | GO:0008152; metabolic process | GO:2000757; negative regulation of peptidyl-lysine acetylation | 2.594E-04 | 8.173E-03 | HDAC1, HDAC2, HDAC8 |
| BP | GO:0008152; metabolic process | GO:0006066; alcohol metabolic process | 2.634E-04 | 8.277E-03 | AKR1B1, AKR1B10, ALDH1A1, APP, CYP1B1, CYP3A4, NPC1, RXRA |
| BP | GO:0050896; response to stimulus | GO:0070848; response to growth factor | 2.833E-04 | 8.763E-03 | AKT1, APP, HDAC2, HDAC6, KDR, MAPK1, MAPK14, SRC |
| BP | GO:0032501; multicellular organismal process | GO:0003014; renal system process | 2.833E-04 | 8.763E-03 | AKR1B1, BCL2, DRD2, HSD11B2, PKN1 |
| BP | GO:0032501; multicellular organismal process | GO:0019233; sensory perception of pain | 2.882E-04 | 8.875E-03 | CNR1, CNR2, MAPK1, PTGS2 |
| BP | GO:0009987; cellular process | GO:0071216; cellular response to biotic stimulus | 2.918E-04 | 8.961E-03 | AXL, MAPK14, NFKB1, SRC, SYK, TP53 |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 2.952E-04 | 9.054E-03 | ACHE, AKT1, BCL2, BLM, DRD2, HPGD, KCNH2, MAPT, MCL1, NFKB1, NQO2, PTGS2, UGT1A1, XDH |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 2.990E-04 | 9.094E-03 | HPGD, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0030520; intracellular estrogen receptor signaling pathway | 2.990E-04 | 9.094E-03 | ESR1, ESR2, SRC |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 3.133E-04 | 9.461E-03 | AXL, MET, PIK3CA, PIK3CB, PTK2, SRC |
| BP | GO:0008152; metabolic process | GO:0033138; positive regulation of peptidyl-serine phosphorylation | 3.268E-04 | 9.857E-03 | AKT1, APP, BCL2, PIK3CA, PTGS2 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.203E-17 | 2.998E-14 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.195E-16 | 1.369E-13 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 4.875E-24 | 9.457E-22 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 4.989E-14 | 3.762E-12 | MAP2K1; SRC; MMP2; PIK3CB; MAPK14; HIF1A; ESR1; MMP9; PTK2; IGF1R; PIK3CA; KDR; AKT1; MAPK1; TP53; MET |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 5.817E-14 | 3.762E-12 | HDAC2; HDAC3; HDAC10; SYK; SRC; HDAC1; PIK3CB; HDAC8; NFKB1; HDAC6; POLB; PKM; PIK3CA; CDK1; MAPK1; TP53 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.478E-12 | 5.733E-11 | MAP2K1; HDAC2; HDAC1; MMP1; MMP2; PIK3CB; PTGS2; HIF1A; MMP9; NFKB1; PTK2; IGF1R; RXRA; PIK3CA; BCL2; AKT1; MAPK1; MET; TP53 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.764E-13 | 8.557E-12 | MAP2K1; HDAC2; HDAC3; SRC; HDAC1; PIK3CB; ESR1; HIF1A; RXRA; PIK3CA; AKT1; MAPK1; TP53 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.042E-12 | 6.602E-11 | MAP2K1; PIK3CA; SRC; KDR; AKT1; MAPK1; PIK3CB; MAPK14; PTGS2; PTK2 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.151E-11 | 2.792E-10 | MAP2K1; PIK3CA; SRC; AKT1; MAPK1; PIK3CB; MAPK14; ESR1; NFKB1; ESR2 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 5.455E-12 | 1.512E-10 | MAP2K1; PKM; PIK3CA; HKDC1; AKT1; MAPK1; PIK3CB; TP53; MET; HIF1A |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.335E-10 | 2.590E-09 | MAP2K1; SYK; PIK3CB; PTK2; NFKB1; IGF1R; RXRA; PIK3CA; KDR; BCL2; AKT1; MAPK1; PKN1; TP53; MET; MCL1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.950E-11 | 1.067E-09 | CYP2C9; APP; MAP2K1; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 2.652E-10 | 4.677E-09 | MAP2K1; PIK3CA; PLK1; CDK1; AKT1; MAPK1; PIK3CB; MAPK14; CDC25B; IGF1R |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.936E-10 | 4.746E-09 | MAP2K1; PIK3CA; SRC; MMP2; AKT1; MAPK1; PIK3CB; ESR1; MMP9; ESR2 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.858E-10 | 5.758E-09 | MAP2K1; HDAC2; PIK3CA; HDAC1; AKT1; MAPK1; PIK3CB; TP53; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 4.360E-10 | 6.042E-09 | MAP2K1; PIK3CA; HKDC1; BCL2; AKT1; MAPK1; PIK3CB; HIF1A; NFKB1; IGF1R |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.130E-09 | 1.370E-08 | ALK; MAP2K1; RXRA; PIK3CA; AKT1; MAPK1; PIK3CB; TP53 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.947E-09 | 1.988E-08 | MAP2K1; HDAC1; PTGS2; MMP9; NFKB1; CDC25B; PIK3CA; PIM1; BCL2; CYP1B1; MAPK1; TP53; MET; MCL1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.229E-09 | 2.160E-08 | HDAC2; SYK; CSNK2A1; PIK3CA; HDAC1; BCL2; CDK1; AKT1; PIK3CB; MAPK14; TP53; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.338E-09 | 2.160E-08 | MAP2K1; PIK3CA; BCL2; AKT1; MAPK1; PIK3CB; TP53; NFKB1; IGF1R |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 3.654E-09 | 3.082E-08 | MAP2K1; PIK3CA; SRC; CNR1; KDR; AKT1; MAPK1; PIK3CB; MAPK14; DRD2; MET; IGF1R |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.716E-09 | 1.850E-08 | RXRA; PIK3CA; BCL2; AKT1; PIK3CB; PTGS2; TP53; NFKB1; PTK2 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 7.250E-09 | 5.860E-08 | PIK3CA; MMP2; PIM1; BCL2; AKT1; MAPK1; PIK3CB; MAPK14; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.115E-09 | 1.370E-08 | HSD11B1; CYP2C9; UGT1A1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.866E-09 | 6.371E-08 | MAP2K1; PIK3CA; LMNA; BCL2; AKT1; MAPK1; PIK3CB; TP53; NFKB1; MCL1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.510E-09 | 1.723E-08 | HSD11B1; HSD11B2; UGT1A1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.329E-08 | 9.205E-08 | MAP2K1; PIK3CA; SRC; BCL2; AKT1; MAPK1; PIK3CB; TP53; MMP9; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 8.005E-09 | 5.973E-08 | HDAC2; RXRA; HPGD; HDAC1; TP53; MMP9; MET; ELANE; NFKB1; PTK2; IGF1R |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 7.873E-09 | 5.973E-08 | MAP2K1; PIK3CA; AKT1; MAPK1; PIK3CB; TP53; MET; IGF1R |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.446E-08 | 2.026E-07 | MAOA; ALOX15; AKR1B1; ALOX12; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; HSD11B1; FUT7; ALOX5; XDH; UGT1A1; GAA; PGD; CYP2C9; PKM; AKR1B10; HKDC1; CYP1A2; ALDH1A1; CYP1A1; ALPL |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.544E-08 | 1.033E-07 | MAP2K1; PIK3CA; AKT1; MAPK1; PIK3CB; MAPK14; PTGS2; MMP9; NFKB1 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.649E-08 | 1.713E-07 | MAP2K1; PIK3CA; SRC; KDR; BCL2; AKT1; MAPK1; PIK3CB; MET; PTK2; IGF1R |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.312E-08 | 2.008E-07 | MAP2K1; PIK3CA; BCL2; AKT1; MAPK1; PIK3CB; MAPK14; TP53; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 3.312E-08 | 2.008E-07 | MAP2K1; PIK3CA; BCL2; AKT1; MAPK1; PIK3CB; MAPK14; TP53; NFKB1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.512E-09 | 3.082E-08 | MAP2K1; MMP1; SRC; MMP2; MAPK1; MMP9; TP53 |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 9.222E-08 | 4.835E-07 | MAP2K1; HDAC2; HDAC3; HDAC10; MAOA; HDAC1; MAPK1; DRD2; HDAC8; HDAC6 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.827E-08 | 2.183E-07 | MAP2K1; PIK3CA; PIM1; AKT1; MAPK1; PIK3CB; NFKB1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 9.699E-08 | 4.951E-07 | MAP2K1; PIK3CA; AKT1; MAPK1; PIK3CB; TP53; IGF1R |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 6.950E-08 | 3.745E-07 | MAP2K1; PIK3CA; BCL2; AKT1; MAPK1; PIK3CB; TP53 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 4.319E-07 | 1.862E-06 | PIK3CA; ALOX5; BCL2; AKT1; MAPK1; PIK3CB; MAPK14; NFKB1 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 5.577E-07 | 2.302E-06 | PIK3CA; SYK; SRC; AKT1; MAPK1; PIK3CB; MAPK14; PTGS1 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.331E-07 | 6.299E-07 | MAP2K1; PIK3CA; SYK; AKT1; MAPK1; PIK3CB; MAPK14 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.080E-07 | 5.237E-07 | MAP2K1; PIK3CA; AKT1; MAPK1; PIK3CB; TP53; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.185E-07 | 9.857E-07 | MAP2K1; PIK3CA; SYK; AKT1; MAPK1; PIK3CB; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 6.950E-08 | 3.745E-07 | CYP2C9; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.080E-07 | 5.237E-07 | MAP2K1; PIK3CA; AKT1; MAPK1; PIK3CB; MET; HIF1A |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.016E-06 | 3.866E-06 | MAP2K1; PIK3CA; SYK; AKT1; MAPK1; PIK3CB; MAPK14; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.453E-06 | 5.220E-06 | MAP2K1; PIK3CA; SRC; GRK6; AKT1; MAPK1; PIK3CB; NFKB1; PTK2 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.076E-06 | 3.940E-06 | RXRA; PIK3CA; AKT1; MAPK1; PIK3CB; MAPK14; TP53; NFKB1 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.076E-06 | 3.940E-06 | MAP2K1; PIK3CA; PLK1; AKT1; MAPK1; PIK3CB; MAPK14; IGF1R |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.185E-07 | 9.857E-07 | HSD11B1; CYP2C9; UGT1A1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 7.329E-07 | 2.902E-06 | MAP2K1; PIK3CA; SRC; AKT1; MAPK1; PIK3CB; PTK2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.429E-06 | 8.219E-06 | HCAR2; MAP2K1; PIK3CA; AKT1; MAPK1; PIK3CB; DRD2; NFKB1; TSHR |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 7.101E-06 | 2.187E-05 | MAP2K1; PIK3CA; KDR; AKT1; MAPK1; PIK3CB; MET; NFKB1; IGF1R |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 3.800E-06 | 1.208E-05 | ACHE; MAP2K1; PIK3CA; BCL2; AKT1; MAPK1; PIK3CB |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.792E-06 | 9.181E-06 | MAP2K1; PIK3CA; AKT1; MAPK1; PIK3CB; MAPK14; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.457E-06 | 8.219E-06 | MAP2K1; PIK3CA; AKT1; MAPK1; PIK3CB; MAPK14; NFKB1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.670E-05 | 4.966E-05 | PTPN1; MAP2K1; PIK3CA; HKDC1; AKT1; MAPK1; PIK3CB |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.919E-05 | 5.474E-05 | MAP2K1; PIK3CA; AKT1; MAPK1; PIK3CB; MAPK14; IGF1R |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 5.473E-07 | 2.302E-06 | MAP2K1; PIK3CA; AKT1; MAPK1; PIK3CB; TP53 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 8.566E-07 | 3.324E-06 | PIK3CA; AKT1; PIK3CB; PTGS2; TSHR; PTGS1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 7.287E-05 | 1.860E-04 | MAP2K1; PIK3CA; AKT1; MAPK1; PIK3CB; MAPK14; NFKB1 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.690E-05 | 4.966E-05 | MAP2K1; PIK3CA; SYK; AKT1; MAPK1; PIK3CB |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 4.313E-07 | 1.862E-06 | ALOX5; CYP1A1; CYP1B1; PTGS2; CYP19A1; IGF1R |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.796E-05 | 5.201E-05 | PIK3CA; AKT1; PIK3CB; TP53; NFKB1; IGF1R |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 1.905E-06 | 6.719E-06 | HDAC2; PIK3CA; HDAC1; AKT1; PIK3CB; IGF1R |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.215E-04 | 2.874E-04 | MAP2K1; AKT1; MAPK1; MAPT; MAPK14; TP53; NFKB1; CDC25B |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 8.108E-05 | 2.017E-04 | SYK; SRC; BCL2; AKT1; MAPK1; MAPK14; NFKB1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.705E-05 | 7.290E-05 | MAP2K1; PIK3CA; AKT1; MAPK1; PIK3CB; HIF1A |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 3.194E-05 | 8.488E-05 | PIK3CA; AKT1; MAPK1; PIK3CB; MAPK14; NFKB1 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 6.494E-05 | 1.680E-04 | PIK3CA; MMP2; PIK3CB; MAPK14; MMP9; PTK2 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.423E-04 | 3.287E-04 | PIK3CA; CSNK2A1; AKT1; PIK3CB; TP53; NFKB1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 4.490E-06 | 1.405E-05 | PTPN1; CSNK2A1; SRC; MAPK1; MET; IGF1R |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.089E-06 | 7.236E-06 | CYP2C9; UGT1A1; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 8.557E-05 | 2.075E-04 | HDAC2; HDAC1; PLK1; CDK1; TP53; CDC25B |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.944E-04 | 4.335E-04 | MAP2K1; PIK3CA; SYK; AKT1; MAPK1; PIK3CB |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 2.255E-04 | 4.916E-04 | PIK3CA; BCL2; AKT1; MAPK1; PIK3CB; MAPK14 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 3.207E-04 | 6.763E-04 | PIK3CA; PIM1; BCL2; AKT1; PIK3CB; MCL1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.975E-06 | 9.619E-06 | CYP2C9; UGT1A1; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 3.207E-04 | 6.763E-04 | MAP2K1; PIK3CA; SRC; MAPK1; PIK3CB; PTGS2 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 1.563E-03 | 2.945E-03 | MAP2K1; PIK3CA; SRC; MAPK1; PIK3CB; PTK2 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.275E-02 | 3.507E-02 | CNR2; CNR1; DRD2; DRD3; TSHR |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.758E-02 | 2.751E-02 | SRC; GRK6; KDR; MET; IGF1R |
| hsa05016 | Huntington's disease_Homo sapiens_hsa05016 | 2.609E-02 | 3.986E-02 | HDAC2; HDAC1; HTT; TP53 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.880E-03 | 3.473E-03 | RXRA; PIK3CA; AKT1; PIK3CB; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 2.278E-02 | 3.507E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 4.351E-04 | 8.979E-04 | PTPN1; PIK3CA; AKT1; PIK3CB; NFKB1 |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 1.146E-03 | 2.201E-03 | MAP2K1; PIK3CA; SYK; MAPK1; PIK3CB |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 3.960E-03 | 6.798E-03 | POLB; PIK3CA; AKT1; PIK3CB; TP53; NFKB1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 7.546E-04 | 1.509E-03 | MAP2K1; PLK1; CDK1; MAPK1; IGF1R |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.881E-04 | 4.244E-04 | MAP2K1; SRC; MMP2; MAPK1; MAPK14 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 2.660E-04 | 5.734E-04 | PIK3CA; SRC; ALOX12; PIK3CB; MAPK14 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 2.910E-03 | 5.133E-03 | MAP2K1; PIK3CA; AKT1; MAPK1; PIK3CB |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 9.352E-04 | 1.814E-03 | MAOA; AKT1; MAPK14; DRD2; DRD3 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.986E-03 | 5.219E-03 | BACE1; APP; MAPK1; MAPT; HSD17B10 |
| hsa01200 | Carbon metabolism_Homo sapiens_hsa01200 | 2.808E-02 | 4.256E-02 | PKM; HKDC1; PGD |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 2.083E-04 | 4.592E-04 | SYK; CSNK2A1; BCL2; PTGS2; NFKB1 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 5.909E-03 | 9.798E-03 | PIK3CA; AKT1; PIK3CB; IGF1R |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.607E-04 | 3.667E-04 | MAP2K1; SRC; CDK1; MAPK1; DRD2 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 2.746E-03 | 4.979E-03 | PIK3CA; PIK3CB; NFKB1; PTK2 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 9.066E-05 | 2.171E-04 | PIK3CA; SRC; PIK3CB; MET; PTK2 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 2.847E-03 | 5.113E-03 | CNR1; MAPK1; MAPK14; PTGS2 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.775E-05 | 1.514E-04 | SLCO1B1; RXRA; CA2; SLCO1B3; CYP3A4 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.548E-05 | 7.063E-05 | PIK3CA; AKT1; MAPK1; PIK3CB; HIF1A |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.582E-03 | 2.951E-03 | MAPK1; PKN1; MAPK14; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 8.591E-04 | 1.684E-03 | MAPK1; MAPK14; PTGS2; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 9.482E-03 | 1.533E-02 | MAPK1; MAPK14; NFKB1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 7.848E-03 | 1.279E-02 | RXRA; AKT1; NFKB1 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 6.573E-04 | 1.328E-03 | SRC; MAPK14; MET; NFKB1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 8.445E-06 | 2.560E-05 | PKM; PIK3CA; HKDC1; MAPK1; PIK3CB |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 5.538E-04 | 1.131E-03 | SRC; MAPK1; MAPK14; NFKB1 |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 5.116E-03 | 8.556E-03 | MAP2K1; MAPK1; IGF1R |
| hsa04330 | Notch signaling pathway_Homo sapiens_hsa04330 | 3.163E-02 | 4.720E-02 | HDAC2; HDAC1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 4.430E-03 | 7.473E-03 | MAPK1; MAPK14; NFKB1 |
| hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 4.214E-03 | 7.171E-03 | UGT1A1; GAA; HKDC1 |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 3.233E-03 | 5.600E-03 | BCL2; MAPK14; TP53 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.884E-03 | 5.133E-03 | MAOA; DRD2; NFKB1 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 1.332E-04 | 3.114E-04 | PIK3CA; HKDC1; AKT1; PIK3CB |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 6.394E-07 | 2.584E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 7.554E-05 | 1.903E-04 | HSD11B2; PIK3CA; MAPK1; PIK3CB |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.407E-03 | 4.405E-03 | UGT1A1; CYP3A4; XDH |
| hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 1.752E-02 | 2.751E-02 | MAP2K1; MAPK1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 8.356E-05 | 2.052E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 2.281E-05 | 6.414E-05 | MAP2K1; RXRA; MAPK1; TP53 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.566E-02 | 2.490E-02 | POLB; APEX1 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 1.065E-02 | 1.707E-02 | MAP2K1; MAPK1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 2.620E-05 | 7.160E-05 | AKR1B10; GAA; HKDC1; AKR1B1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 8.341E-04 | 1.651E-03 | AKR1B10; HKDC1; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.181E-03 | 2.245E-03 | AKR1B10; UGT1A1; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 7.792E-03 | 1.279E-02 | CA2; CA4 |
| hsa00524 | Butirosin and neomycin biosynthesis_Homo sapiens_hsa00524 | 2.867E-02 | 4.311E-02 | HKDC1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.297E-04 | 6.878E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; BCL2; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; CNR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| NA: NA | Vomiting | NA | DRD2 |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1; IGF1R; MMP9; TP53; KDR |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; PTK2; TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| NA: NA | False perceptions | NA | DRD2 |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2 |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| NA: NA | Menopausal disorder | NA | ESR1 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3 |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | SLC6A2 |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| NA: NA | Peripheral vasoconstriction | NA | DRD2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; SYK; ELANE; PTGS1; PTGS2; MAPK14; DRD2; CNR2 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | CNR1 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | SLC6A2; SLC6A2 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; CNR1; CNR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| NA: NA | Itching | NA | DRD2 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; CNR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD2 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; TP53; TP53; PLK1 |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | ELANE; ELANE; ELANE; MAPK14 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; NQO2; IGF1R; CYP19A1; CDK1; BCL2; ESR1; ESR1; DRD2; KDR; KDR; KDR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; CNR1; KDR; KDR; KDR; KDR |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; ESR1; CNR2 |
| J00-J99: Diseases of the respiratory system | Mucolytic | J00-J99 | ELANE |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| C00-D49: Neoplasms | Cutaneous T-cell lymphoma | C84.0, C84.1 | RXRA |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PKM; ACHE; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; IGF1R; CNR1; CDK1; SLC6A2; ESR1; DRD2; CNR2 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| NA: NA | Malignant essential hypertension | NA | DRD2 |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chemotherapy-induced nausea | R11 | CNR1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| NA: NA | Acute respiratory distress syndrome | NA | ELANE; ELANE; ELANE; MAPK14 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; SYK; DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; PTGS2; DRD2; APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | CNR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1; PTGS2; PTGS2; CNR1; CNR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2 |
| NA: NA | Corneal vascularity | NA | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| C00-D49: Neoplasms | AML | NA | KDR |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PLK1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; MMP2; PTGS2; KDR; PLK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; ACHE; DRD2 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; PLK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; PTPN1; CNR1; CNR1; CNR1; CNR1; CNR1; CNR1; SLC6A2 |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anorexia | F50.0-F50.1 | CNR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; HSD11B1; HSD11B1; PTPN1; CNR1; CNR1; CNR1 |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; ACHE; SLC6A2; CYP3A4; DRD2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; ELANE; ELANE; MAPK14; DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; PKM; SYK; PIK3CA; CA9; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TP53; PIK3CB; KDR; KDR; KDR; PLK1; PLK1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | ELANE; ELANE |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | ELANE |
| NA: NA | Myocardial ischaemia-reperfusion injury | NA | ELANE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; SLC6A2; SLC6A2; SLC6A2; SLC6A2 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AKT1; MET; MCL1; HDAC6; CSNK2A1; SYK; PIK3CA; CA1; CA9; HDAC10; MMP2; NQO2; ACHE; PTGS2; SRC; IGF1R; PTK2; HIF1A; HDAC8; CDK1; MAPK1; MAPK14; MMP9; NFKB1; PIM1; CDC25B; BCL2; BCL2; TP53; PIK3CB; ESR1; ESR1; KDR; PLK1; APP |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2 |
| J00-J99: Diseases of the respiratory system | Bronchiectasis | J47, Q33.4 | ELANE |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2 |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; SLC6A2; DRD2; HCAR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; CNR2 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | ELANE |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2 |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HCAR2; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CNR1; DRD3; DRD2; DRD2; DRD2; DRD2 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| C00-D49: Neoplasms | Glioma | C71 | KDR; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; PTGS2; PTGS2; MAPK14; MMP1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HCAR2 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; ALOX5; HCAR2 |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2; MAPK14 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; ALOX5; SYK; ELANE; PTGS2; PTGS2; PTGS2; PTGS2; MAPK14; MMP1; CNR2 |
| NA: NA | Schizoaffective disorders | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2; DRD2; DRD2; DRD2; DRD2 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2 |
| NA: NA | Edema | NA | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3; DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | CNR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; SLC6A2 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; PTGS1; ESR1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; DRD2 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | CNR1; DRD3; DRD2 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; PTGS2; IGF1R; IGF1R; AXL; DRD2; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; BCL2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; DRD3 |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; APP |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; AURKB; TP53 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| NA: NA | Hyperaemia | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | CNR1; DRD3 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK; PIK3CB |
| J00-J99: Diseases of the respiratory system | Pulmonary emphysema | J43 | ELANE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2 |
| J00-J99: Diseases of the respiratory system | Pulmonary disease | J00-J99 | ELANE |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; MAPK14; BCL2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| C00-D49: Neoplasms | Prostate cancer | C61 | BCL2; ESR1; PLK1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | CNR1; DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; CNR1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; SYK; SYK; ELANE; PTGS2; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B2; HSD11B1; PTPN1; PTPN1; PTGS2; CNR1; NFKB1; HCAR2 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; HCAR2 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CNR1; DRD2; DRD2 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CNR1; CA2; DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; MAPK14; DRD2; CNR2 |
| NA: NA | Inflammatory diseases | NA | DRD2 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; PTGS2; XDH |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; MAPK14 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A; BCL2; PLK1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; PTGS1; HDAC2 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | HDAC6; SRC; IGF1R; BCL2 |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |